Sign In
Buy OPRX
$6.55
+0.140 (+2.18%)
At Close: Jul 13, 2026
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
07:30am, Tuesday, 30'th Jun 2026
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
07:30am, Thursday, 25'th Jun 2026
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables
OptimizeRx to Participate in Upcoming Investor Conferences
07:30am, Monday, 01'st Jun 2026
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healt
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
12:06pm, Thursday, 28'th May 2026
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network
07:30am, Thursday, 21'st May 2026
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastruc
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
11:41am, Wednesday, 20'th May 2026
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
09:50am, Wednesday, 20'th May 2026
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
11:10am, Friday, 15'th May 2026
OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous r
OptimizeRx Q1 Earnings Call Highlights
10:06pm, Tuesday, 12'th May 2026
OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life scien
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript
08:30pm, Tuesday, 12'th May 2026
OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
06:16pm, Tuesday, 12'th May 2026
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.08 per share a year ago.
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
04:01pm, Tuesday, 12'th May 2026
– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA gu
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
01:05pm, Tuesday, 12'th May 2026
OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
07:30am, Monday, 11'th May 2026
Expands life sciences marketers' reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx's trusted EHR network for the first time Expands life sciences marketers' rea
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
11:30am, Thursday, 07'th May 2026
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
